Peru Medical Device Registration: Common Misconceptions and Costly Errors

Regulatory information verified as of October 29, 2026.

1. Key takeaways

CE marking or FDA approval does not constitute an import license in Peru and does not substitute for the sanitary registration. Every device placed on the Peruvian market requires an independent sanitary registration (RS); exhibition samples, personal-use equipment and research devices have their own boundaries, all subject to DIGEMID determination. The validity of a Peruvian sanitary registration is 5 years (D.S. N° 016-2011-SA, published 2011-07-27), not the 7 years that circulates in industry commentary, and expiry of the review period without a reply triggers negative administrative silence, which is not an approval. The eight boundaries below are the costliest judgment errors GRZAN has repeatedly encountered in project due diligence.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: Foreign approval is evidence, not an exemption.

Approvals from countries of high sanitary vigilance (France, the Netherlands, the United Kingdom, the United States, Canada, Japan, Switzerland, Germany, Spain, Australia, Denmark, Italy and others, with the list subject to official publication) serve in the Peruvian system to raise evidentiary value or to accompany the free sale certificate (CFS); they are one link in the evidence chain. Mechanically, the authority to grant a sanitary registration always remains with DIGEMID, and foreign approval cannot replace the local administrative decision. Treating a CE certificate as a customs document fails directly at clearance, because customs verifies the RS number, not the CE number.

Insight 2: The logic of an unanswered deadline is refusal, not approval.

The clocks set by the current consolidated procedures text, D.S. N° 011-2026-SA published on 2026-07-21, are Class I 22, Class II 44, Classes III/IV 66 working days, and in vitro diagnostic devices 30 working days (practical estimate; article numbers not verified line by line). Expiry of the period without a reply constitutes negative administrative silence: the legal effect is non-approval, and the applicant should file reconsideration (Reconsideración) or appeal (Apelación), not arrange shipments on the assumption of approval. This runs in parallel with the statutory calendar-day ceilings of Art. 136 of the regulation (Class I 30, Class II 60, Classes III/IV 90); the two units must not be mixed.

Insight 3: The registration holder solves who holds the certificate, not whether registration is needed.

The registration holder (Titular del Registro Sanitario / PRH) is the bearer of obligations, and its existence does not remove the registration requirement for the product itself. Secondary sources describe D.S. N° 020-2024-SA as amending D.S. N° 016-2011-SA to decouple registration ownership from commercial distribution, so that an independent PRH may hold the certificate while other qualified wholesale distribution companies may separately obtain a sanitary registration certificate (CRS) to import the same registered product; this item is pending verification against primary sources and must not be treated as a settled conclusion. The same instrument is also described, in conflicting accounts, as containing a device price reporting requirement, likewise pending verification.

Insight 4: Special scenarios have their own channels; there is no general exemption.

Devices in the research stage follow the exceptional sanitary authorization of R.M. N° 817-2020/MINSA, published on 2020-10-10, whose effect is limited to the COVID-19 public health emergency; where clinical trials are involved, D.S. N° 021-2017-SA, published on 2017-06-30, applies in the absence of a dedicated device clinical regulation, with the INS approving protocols and results and DIGEMID approving the trial products. In vitro diagnostic devices do not enter Classes I-IV: they are classified under R.M. N° 283-98-SA/DM, published 1998-08-07, and the first supplementary transitional provision of D.S. N° 001-2012-SA, published 2012-01-22, points them to the D.S. N° 010-97-SA channel, published 1997-12-23, with a review clock of 30 working days.

4. Practical recommendations

1. Fix the registration need at project start: make whether an RS is required the first question; foreign approval is one item on the evidence list and is never written into the customs assumption.
2. Add a remedy branch to the clock log: log the 22 / 44 / 66 working days clock and pre-plan the reconsideration and appeal actions after expiry, with the 15-working-day filing deadline.
3. Compute validity on the 5-year basis: derive expiry from the granting date and start re-registration 1 year early; never use the 7-year figure.
4. Route special scenarios through their own channels: assess research devices under R.M. N° 817-2020/MINSA, and run clinical trials under D.S. N° 021-2017-SA with dual approval by the INS and DIGEMID.
5. Do not cite penalty amounts as settled figures: secondary sources mention a penalty ceiling of 10 UIT, which must not be used as a confirmed amount; for any conversion, the sole verified basis is the 2026 UIT of S/ 5,500 (D.S. N° 301-2025-EF, published 2025-12-17, effective 2026-01-01).

5. Verification checklist

□ Confirmed that the target product requires an independent RS, with CE/FDA used as evidence only

□ Confirmed that sanitary registration validity is 5 years and the 7-year figure is not used

□ Confirmed that negative administrative silence means non-approval, with remedies of reconsideration and appeal

□ Confirmed that the review clock and the Art. 136 calendar-day ceilings are recorded separately, with units not mixed

□ Confirmed that in vitro diagnostic devices follow the parallel channel (30 working days) and are not merged into Classes I-IV

□ Confirmed that research devices and clinical trials are assessed under R.M. N° 817-2020/MINSA and D.S. N° 021-2017-SA respectively

□ Confirmed that conclusions on D.S. N° 020-2024-SA are marked as pending verification against primary sources and not stated as settled

□ Confirmed that penalty amounts are not cited as settled figures and the UIT basis of S/ 5,500 is used

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides medical device registration support in Peru for manufacturers, importers and authorized representatives. For inquiries, contact info@grzanglobal.com.